MedPath

Roche Holding AG

Roche Holding AG logo
🇨🇭Switzerland
Ownership
Public
Established
1896-01-15
Employees
103.6K
Market Cap
$270.5B
Website
http://www.roche.com

A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) Treatment in Patients With Rheumatoid Arthritis

Completed
Conditions
Rheumatoid Arthritis
First Posted Date
2013-09-30
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
169
Registration Number
NCT01952509

A Study of RO6811135 in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Metformin

Phase 2
Withdrawn
Conditions
Diabetes Mellitus Type 2
Interventions
Drug: Placebo
Drug: RO6811135
First Posted Date
2013-09-26
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Registration Number
NCT01951183

An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
First Posted Date
2013-09-26
Last Posted Date
2016-09-21
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
52
Registration Number
NCT01951170

A Study to Measure Serum Periostin, Asthma-Related Biomarkers and Response to Prednisolone in Adult and Adolescent Patients With Severe Oral Corticosteroid-Dependent Asthma

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: LABA
Drug: corticosteroids
Drug: prednisolone
First Posted Date
2013-09-23
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
54
Registration Number
NCT01948401

A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis

First Posted Date
2013-09-13
Last Posted Date
2018-11-13
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
100
Registration Number
NCT01941095
Locations
🇬🇷

Laiko General Hospital; Dept. of Pathophysiology-Uni of Athens, Athens, Greece

🇬🇷

Uni Hospital of Ioannina; Rheumatology, Ioannina, Greece

🇬🇷

General Hospital of Thessaloniki HIPPOKRATIO; Clinical Immunology Unit,2nd Dept of Internal Medicine, Thessaloniki, Greece

and more 7 locations

A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration

Phase 1
Completed
Conditions
Macular Degeneration
Interventions
Drug: RO6867461
First Posted Date
2013-09-13
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
24
Registration Number
NCT01941082

A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Tocilizumab
Drug: DMARDs
First Posted Date
2013-09-13
Last Posted Date
2017-07-11
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
227
Registration Number
NCT01941940
Locations
🇮🇹

Osp S. Maria Misericordia Dip. Medicina Clinica Sperimentale Cattedra Reumatologia, Perugia, Umbria, Italy

🇮🇹

Uni Degli Studi Di L Aquila; Cattedra Di Reumatologia - Dept. Di Medicina Interna E San, Coppito, Abruzzo, Italy

🇮🇹

Ospedale Regionale Torrette; SOD Clinica Medica del Dipartimento di Medicina Interna e Specialisti, Ancona, Marche, Italy

and more 46 locations

A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2013-09-12
Last Posted Date
2020-11-03
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
240
Registration Number
NCT01940497
Locations
🇮🇹

Ospedale S.G.Calibita Fatebenefratelli; Unità Operativa Oncologia, Roma, Lazio, Italy

🇮🇹

Campus Universitario S.Venuta; Centro Oncologico T.Campanella, Catanzaro, Calabria, Italy

🇮🇹

Ospedale San Carlo; Day Hospital Oncologia Medica, Potenza, Basilicata, Italy

and more 51 locations

An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis

Completed
Conditions
Anemia
Interventions
Drug: Methoxy polyethylene glycol epoetin beta
First Posted Date
2013-09-12
Last Posted Date
2017-07-05
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
98
Registration Number
NCT01940484
Locations
🇿🇦

Donald Gordon Medical Centre, Johannesburg, South Africa

🇿🇦

Universitas Private Hospital, Bloemfontein, South Africa

🇿🇦

Glynnwood Hospital, Benoni, South Africa

and more 7 locations

A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: RO5424802
Drug: rifampin
First Posted Date
2013-09-12
Last Posted Date
2016-12-21
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
24
Registration Number
NCT01940510
© Copyright 2025. All Rights Reserved by MedPath